[go: up one dir, main page]

NO20030128L - Behandling av B celle ondartethet ved anvendelse av kombinasjon av B cellereduserende antistoff og immun-modulerende antistoff beslektedeapplikasjoner - Google Patents

Behandling av B celle ondartethet ved anvendelse av kombinasjon av B cellereduserende antistoff og immun-modulerende antistoff beslektedeapplikasjoner

Info

Publication number
NO20030128L
NO20030128L NO20030128A NO20030128A NO20030128L NO 20030128 L NO20030128 L NO 20030128L NO 20030128 A NO20030128 A NO 20030128A NO 20030128 A NO20030128 A NO 20030128A NO 20030128 L NO20030128 L NO 20030128L
Authority
NO
Norway
Prior art keywords
cell
antibody
treatment
combination
related applications
Prior art date
Application number
NO20030128A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030128D0 (no
Inventor
Nabil Hanna
Kandasamy Hariharan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/772,938 external-priority patent/US20020006404A1/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of NO20030128D0 publication Critical patent/NO20030128D0/no
Publication of NO20030128L publication Critical patent/NO20030128L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20030128A 2000-07-12 2003-01-10 Behandling av B celle ondartethet ved anvendelse av kombinasjon av B cellereduserende antistoff og immun-modulerende antistoff beslektedeapplikasjoner NO20030128L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21770600P 2000-07-12 2000-07-12
US09/772,938 US20020006404A1 (en) 1999-11-08 2001-01-31 Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
PCT/US2001/015677 WO2002004021A1 (fr) 2000-07-12 2001-05-16 Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire

Publications (2)

Publication Number Publication Date
NO20030128D0 NO20030128D0 (no) 2003-01-10
NO20030128L true NO20030128L (no) 2003-03-12

Family

ID=26912176

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030128A NO20030128L (no) 2000-07-12 2003-01-10 Behandling av B celle ondartethet ved anvendelse av kombinasjon av B cellereduserende antistoff og immun-modulerende antistoff beslektedeapplikasjoner

Country Status (11)

Country Link
EP (1) EP1305045A1 (fr)
JP (1) JP2004502742A (fr)
KR (2) KR20030031957A (fr)
CN (1) CN1446104A (fr)
AU (2) AU2001264612C1 (fr)
CA (1) CA2415100A1 (fr)
IL (1) IL153764A0 (fr)
MX (1) MXPA03000306A (fr)
NO (1) NO20030128L (fr)
SG (1) SG136804A1 (fr)
WO (1) WO2002004021A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
EP2052742A1 (fr) * 2000-06-20 2009-04-29 Biogen Idec Inc. Traitement de maladies liées aux lymphocytes B telles des tumeurs et des maladies auto-immunes utilisant une combinaison d'anticorps anti-CD20 froid et d'anticorps anti-CD22 radiomarqué
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
ATE391174T1 (de) 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd Modifizierter tpo-agonisten antikörper
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002243718B2 (en) * 2001-01-31 2007-12-06 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
WO2002078766A2 (fr) * 2001-04-02 2002-10-10 Genentech, Inc. Polytherapie
WO2003068268A2 (fr) * 2002-02-14 2003-08-21 Bioinvent International Ab Traitement, diagnostic et imagerie d'une maladie
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CA2502552C (fr) 2002-10-17 2019-02-12 Genmab A/S Anticorps monoclonaux humains anti-cd20
UA89350C2 (uk) 2002-12-16 2010-01-25 Дженентек, Інк. Гуманізоване антитіло, що зв'язує людський cd20
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US20070003556A1 (en) * 2003-03-31 2007-01-04 Masayuki Tsuchiya Modified antibodies against cd22 and utilization thereof
SI1613350T1 (sl) 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
EP2272868B1 (fr) 2003-06-05 2015-03-04 Genentech, Inc. Thérapie de combinaison pour des désordres de cellules B
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2544368C (fr) * 2003-11-04 2014-04-01 Chiron Corporation Procedes de therapie pour des cancers lies a la cellule b
ES2708095T3 (es) 2003-11-05 2019-04-08 Roche Glycart Ag Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
WO2005117978A2 (fr) 2004-06-04 2005-12-15 Genentech, Inc. Methode de traitement de la sclerose en plaques
CA2597924C (fr) * 2005-02-15 2018-10-02 Duke University Anticorps anti-cd19 et leur utilisation en oncologie
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
WO2006106905A1 (fr) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2007014278A2 (fr) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
BRPI0614183A2 (pt) 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc uso de dose única de moléculas de ligação especìficas para cd20
DE602006019977D1 (de) 2005-08-18 2011-03-17 Genmab As Therapie mit anti-cd4-antikörpern und bestrahlung
BRPI0618208A2 (pt) 2005-11-01 2011-08-23 Novartis Ag uso de anticorpos anti-cd40
WO2007062090A2 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
EP2418223A3 (fr) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Protéines de liaison polyvalente à chaîne unique avec une fonction effectrice
PT3327026T (pt) 2007-07-09 2019-10-30 Genentech Inc Prevenção da redução de ligações de dissulfureto durante a produção recombinante de polipéptidos
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
BRPI0911377A8 (pt) * 2008-04-11 2017-12-05 Trubion Pharmaceuticals Inc Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
FI2464725T4 (fi) 2009-08-11 2025-03-21 Hoffmann La Roche Proteiinien tuotanto glutamiinittomassa soluviljelyn elatusaineessa
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
AU2011226672B2 (en) * 2010-03-12 2015-07-23 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
MX376225B (es) 2015-02-24 2025-03-07 Bioatla Llc Proteínas biológicas condicionalmente activas
BR112017026027A2 (pt) 2015-06-08 2018-08-14 Debiopharm Int Sa combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
CN108699144B (zh) 2015-08-28 2022-07-19 德彪发姆国际有限公司 用于检测cd37的抗体和测定
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
KR20250007038A (ko) 2015-10-02 2025-01-13 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
JP7064769B2 (ja) 2015-11-02 2022-05-11 バイオアトラ、エルエルシー 条件的活性型ポリペプチド
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017189805A1 (fr) 2016-04-27 2017-11-02 Abbvie Inc. Méthodes de traitement de maladies dans lesquelles l'activité de l'il-13 est préjudiciable à l'aide d'anticorps anti-il-13
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
KR102840867B1 (ko) 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
JP2021525735A (ja) 2018-05-30 2021-09-27 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７免疫コンジュゲート投薬レジメン
CA3236006A1 (fr) 2021-11-16 2023-05-25 Genentech, Inc. Methodes et compositions pour le traitement du lupus erythemateux dissemine (sle) par mosunetuzumab

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL174721B1 (pl) * 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof

Also Published As

Publication number Publication date
JP2004502742A (ja) 2004-01-29
CN1446104A (zh) 2003-10-01
IL153764A0 (en) 2003-07-06
NO20030128D0 (no) 2003-01-10
AU2001264612B2 (en) 2007-02-22
SG136804A1 (en) 2007-11-29
EP1305045A1 (fr) 2003-05-02
WO2002004021A1 (fr) 2002-01-17
KR20080039547A (ko) 2008-05-07
AU6461201A (en) 2002-01-21
AU2001264612B8 (en) 2007-02-22
WO2002004021A9 (fr) 2003-01-16
MXPA03000306A (es) 2004-04-05
CA2415100A1 (fr) 2002-01-17
KR20030031957A (ko) 2003-04-23
AU2001264612C1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
NO20030128D0 (no) Behandling av B celle ondartethet ved anvendelse av kombinasjon av B cellereduserende antistoff og immun-modulerende antistoff beslektedeapplikasjoner
DK1604680T3 (da) Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DE50112013D1 (de) Deodorantien und antiperspirantien
NO20001446L (no) Fremgangsmåter og anordninger ved undersjöisk produksjonsanlegg
NO20011964D0 (no) Brönnbehandlingsfluider og fremgangsmåter med anvendelse derav
DE60017241D1 (de) Unterwasserbehandlungsanordnung und -verfahren
IS6700A (is) Meðferðarblanda CETP hindra og atórvastatíns
DK1178099T3 (da) Bore- og behandlingsvæsker
NO20022334L (no) Ny sammensetning og anvendelse
NO20030397D0 (no) Amyloid målsökende billeddannende midler og anvendelser av samme
NO20034437D0 (no) Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
DK1216046T3 (da) Hidtil ukendt kombination af loteprednol og antihistaminer
DE60202564D1 (de) Ausrichtungsvorrichtung und Magnetisierungsvorrichtung
DE60220486D1 (de) Zurückschaltungseinrichtung und Zurückschaltungsverfahren
NO20024404L (no) Forbedringer ved og angÕende undersökelse av korrosjon
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20030882D0 (no) Glasskeramikkmasse og anvendelse derav
DE60120291D1 (de) Endoskop und Endoskopkapsel
NO20003555D0 (no) FremgangsmÕte ved fremstilling av konstruksjonselementer og de resulterende elementer
NO20001954D0 (no) Fremgangsmõter og anordninger ved separator
NO20020031D0 (no) Dihydrobenzodiazepiner og deres anvendelse ved behandling av dyslipidemi
DE60239874D1 (de) Kosmetika und makeup-methode
DE60141890D1 (de) Biegeverfahren und biegevorrichtung
NO20023737D0 (no) Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application